01 / À propos

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment of inflammatory lesions of rosacea. It is also developing TLX-015, a medicine for the prevention and treatment of postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, a medication for adrenal insufficiency treatment; TLX-047, a systemic corticosteroid; HH-001, a sacubitril/valsartan sodium tablet; TLX-024, a liquid oral anticonvulsant; TLX-034, an endocrine drug; TWB-201, a Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company offers health food and products; and over-the-counter drugs. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.